

Key Trends for Active Employees and Early Retirees

Based on Paid Claims Through June 2024 Rolling Year

August 2024



Change Healthcare data breach overview

Change Healthcare is a company that provides technology and managed care services to the healthcare industry



- On February 21, 2024, Change
 Healthcare had a cybersecurity event
- Disconnected its systems to prevent further impact
- As a result, some providers were prevented from processing and submitting prescription drug and medical claims to insurance companies



- This included payments to Aetna and Highmark
- GHIP claims were suppressed starting in late February and continuing well into April
- Results in a misrepresentation of how claims are running vs. budget and prior year



 It is our understanding that the backlog created was cleared out by the end of FY24


Executive Summary

- Overall Allowed PMPY trend rose 5.1% from \$9,223 to \$9,692
- Inpatient medical PMPY decreased 4.7%, driven by a decrease of 6.1% in facility charges
 - Surgical admissions decreased by 11.1%; and accounted for 17% of admissions
 - Allowed amounts PMPY for maternity admissions decreased 11.9% alongside a decrease to maternity admits of 10.1%, which led to a decrease in maternity spend of 11.0%
 - Average length of stay for admissions decreased overall by 4.6%
- Outpatient medical PMPY increased by 4.1% from \$5,113 to \$5,322
 - Utilization saw the largest increases for substance abuse (15.0%), supplies and devices (7.8%) and mental health (7.3%)
 - Allowed amount per service increased for substance abuse (23.8%) medical specialty drugs (18.2%), and mental health (13.5%)
 - Outpatient lab net PMPY payments decreased by 24.9%
 - On the medical pharmacy side, the three most costly medications were to treat cancer (Keytruda), multiple sclerosis (Ocrevus), and treatment neutropenia (low white blood cells) in cancer patients (Neulasta)
- Pharmacy payments were driving 28.9% of the cost overall and increased by 16.4% PMPY from the previous rolling year
 - Specialty drugs incurring the largest costs on the pharmacy plan were medications used to treat rheumatoid and psoriatic arthritis and other skin conditions; they were Humira, Stelara, and Tremfya

Overall Trend


Annual Trend

| Aimadi iiciid | | | |
|---------------------------------------|---------------|---------------|--------|
| | Jul 2022 – | Jul 2023 – | % |
| | Jun 2023 | Jun 2024 | Change |
| Allowed Amount | \$922,657,076 | \$987,169,261 | 7.0% |
| Coordination of Benefits ¹ | \$16,670,264 | \$28,202,273 | 69.2% |
| Out of Pocket | \$46,052,139 | \$49,692,714 | 7.9% |
| Net Payment | \$859,934,673 | \$909,274,274 | 5.7% |
| Members Avg Med or Rx | \$100,037 | \$101,852 | 1.8% |
| Allow Amt PMPY | \$9,223 | \$9,692 | 5.1% |
| Allow Amt PEPY | \$20,293 | \$21,164 | 4.3% |
| Net Pay PMPY | \$8,596 | \$8,927 | 3.9% |
| Net Pay PEPY | \$18,913 | \$19,494 | 3.1% |
| | | | |



¹Increase in Coordination of Benefits is largely due to the addition of PrudentRx Claims. Coordination of Benefits for PrudentRx consists of a "residual copay required by the manufacturer or the remaining drug cost after the program benefits are exhausted or unavailable. This amount is billed back to the plan" (CVS Report Definitions, State of DE State Employee Benefits Comm Savings Report). This does not include any savings, which are not included in this report and not included in the overall Allowed Amount.

Overall PMPY Trend




Allowed Amount PMPY Trend

| | Jul 2022 - Jun 2023 | Jul 2023 - Jun 2024 | % Change |
|-------------------|---------------------|---------------------|----------|
| IP Medical | \$1,951 | \$1,860 | -4.7% |
| OP Medical | \$5,113 | \$5,322 | 4.1% |
| Prescription Drug | \$2,096 | \$2,440 | 16.4% |

Overall Eligibility Trend

Annual Eligibility Trend


| Jul 2022 – | Jul 2023 – | _ |
|------------|--|---|
| Jun 2023 | Jun 2024 | % Change |
| 100,010 | 101,819 | 1.8% |
| 45,467 | 46,645 | 2.6% |
| 15,449 | 15,380 | -0.4% |
| 39,093 | 39,794 | 1.8% |
| 2.2 | 2.2 | -0.8% |
| 34.4 | 34.3 | -0.1% |
| 47.0 | 46.9 | -0.2% |
| 49.9 | 49.9 | 0.1% |
| 13.5 | 13.6 | 0.4% |
| | Jun 2023 100,010 45,467 15,449 39,093 2.2 34.4 47.0 49.9 | Jun 2023 Jun 2024 100,010 101,819 45,467 46,645 15,449 15,380 39,093 39,794 2.2 2.2 34.4 34.3 47.0 46.9 49.9 49.9 |





Overall Trend by Type of Service

| | Allowed Amt PMPY Med and Rx | | | Net Pay Pi | MPY Med and Rx | |
|---------------------|-----------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change |
| IP Facility | \$1,685 | \$1,583 | -6.1% | \$1,601 | \$1,516 | -5.3% |
| IP Professional | \$184 | \$183 | -0.3% | \$175 | \$176 | 0.5% |
| OP Major Procedures | \$1,363 | \$1,388 | 1.8% | \$1,293 | \$1,321 | 2.2% |
| OP Radiology | \$424 | \$458 | 8.0% | \$399 | \$431 | 7.9% |
| OP Office Visits | \$626 | \$661 | 5.7% | \$535 | \$568 | 6.1% |
| OP Lab | \$305 | \$235 | -23.1% | \$273 | \$205 | -24.9% |
| OP Emergency Room | \$626 | \$656 | 4.8% | \$568 | \$597 | 5.0% |
| OP Other | \$420 | \$417 | -0.6% | \$421 | \$431 | 2.4% |
| MHSA | \$375 | \$428 | 14.0% | \$346 | \$395 | 14.0% |
| Prescription Drugs | \$2,096 | \$2,440 | 16.4% | \$1,978 | \$2,147 | 8.5% |

Allowed Amount PMPM Quarterly Trend









Cost and Use by Type of Service


| | Patients as a % of | Costs as a % of |
|---------------------|--------------------|-----------------------------|
| | Total Members | Total Allowed Amount |
| IP Facility | 4.0% | 18.7% |
| IP Professional | 5.2% | 2.2% |
| OP Major Procedures | 16.4% | 16.4% |
| OP Radiology | 37.2% | 5.4% |
| OP Office Visits | 84.4% | 7.8% |
| OP Lab | 61.4% | 2.8% |
| OP Emergency Room | 15.7% | 7.8% |
| OP Other | 78.4% | 4.9% |
| MHSA | 22.4% | 5.1% |
| Prescription Drugs | 76.8% | 28.9% |






Acute Inpatient Admission Detail


| | Jul 2022 – | Jul 2023 – | |
|---|------------|------------|----------|
| | Jun 2023 | Jun 2024 | % Change |
| Medical | 18.4 | 17.9 | -2.3% |
| 8 Maternity | 22.2 | 19.9 | -10.1% |
| Maternity Surgical MHSA | 10.5 | 9.3 | -11.1% |
| 퉏 MHSA | 6.0 | 6.3 | 5.1% |
| Total | 57.0 | 53.5 | -6.2% |
| ≧ Medical | \$609 | \$651 | 6.9% |
| Medical The Maternity Surgical MHSA Total | \$428 | \$377 | -11.9% |
| မို Surgical | \$763 | \$708 | -7.2% |
| ₩ MHSA | \$81 | \$92 | 14.0% |
| € Total | \$1,880 | \$1,828 | -2.8% |
| Medical | \$590 | \$633 | 7.2% |
| ਨੂੰ Maternity | \$403 | \$359 | -11.0% |
| A Maternity A Surgical | \$730 | \$684 | -6.2% |
| MHSA | \$77 | \$88 | 14.4% |
| Total | \$1,800 | \$1,764 | -2.0% |






Admission PMPY Allowed Amount Trend*

| | 11.2022 | 11.2022 | |
|------------------|------------|------------|----------|
| | Jul 2022 – | Jul 2023 – | |
| | Jun 2023 | Jun 2024 | % Change |
| Allowed Amt PMPY | | | |
| Facility | \$1,669 | \$1,566 | -6.2% |
| Professional | \$174 | \$174 | -0.3% |
| Total | \$1,844 | \$1,740 | -5.6% |
| Net Pay PMPY | | | |
| Facility | \$1,588 | \$1,500 | -5.5% |
| Professional | \$166 | \$167 | 0.5% |
| Total | \$1,753 | \$1,667 | -4.9% |
| Professional | \$166 | \$167 | 0. |




Acute Admission Detail*

| | Jul 2022 – | Jul 2023 – | |
|-------------------|------------|------------|-----------|
| | Jun 2023 | Jun 2024 | % Change |
| Length of Stay | 3411 2023 | 3411 202 1 | 70 GHange |
| Medical | 5.8 | 5.5 | -4.7% |
| Surgical | 6.9 | 6.4 | -7.1% |
| Maternity | 3.1 | 2.9 | -7.3% |
| MHSA | 10.4 | 9.7 | -6.7% |
| Total | 5.4 | 5.2 | -4.6% |
| Allowed Amt/Admit | | | |
| Medical | \$33,178 | \$36,295 | 9.4% |
| Surgical | \$72,742 | \$75,970 | 4.4% |
| Maternity | \$19,303 | \$18,917 | -2.0% |
| MHSA | \$13,494 | \$14,639 | 8.5% |
| Total | \$32,995 | \$34,185 | 3.6% |
| Allowed Amt/Day | | | |
| Medical | \$5,741 | \$6,592 | 14.8% |
| Surgical | \$10,601 | \$11,913 | 12.4% |
| Maternity | \$6,150 | \$6,500 | 5.7% |
| MHSA | \$1,292 | \$1,503 | 16.3% |
| Total | \$6,065 | \$6,590 | 8.7% |
| | | | |



Acute Inpatient Admission Detail: Current Year Surgical Admits*




Volume

Top 10 Principal Procedures: 1,111
Total Principal Procedures: 5,449
Top 10 as a % of Total: 20.4%

Cost

Top 10 Principal Procedures (Admission Costs): \$29.4 m
Total Principal Procedures (Admission Costs): \$186.2 m
Top 10 as a % of Total Admission Costs: 15.8%



Outpatient Medical Detail

| | Allowed Amt PMPY Med | | | Patients | | | | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|--|--|
| | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change | | |
| Major Procedures | \$1,363 | \$1,388 | 1.8% | 17,242 | 18,358 | 6.5% | | |
| Specialty Drugs (Medical) | \$598 | \$708 | 18.2% | 3,431 | 3,731 | 8.7% | | |
| Professional Office Visits | \$626 | \$661 | 5.7% | 93,408 | 94,277 | 0.9% | | |
| Emergency Rooms | \$626 | \$656 | 4.8% | 17,397 | 17,562 | 0.9% | | |
| Radiology | \$424 | \$458 | 8.0% | 41,053 | 41,537 | 1.2% | | |
| Other Outpatient Services | \$420 | \$417 | -0.6% | 80,991 | 87,575 | 8.1% | | |
| Laboratory | \$305 | \$235 | -23.1% | 71,125 | 68,614 | -3.5% | | |
| Mental Health | \$266 | \$302 | 13.5% | 23,055 | 24,413 | 5.9% | | |
| Substance Abuse | \$25 | \$31 | 23.8% | 982 | 1,058 | 3 7.7% | | |
| PT, OT, Speech Therapy | \$142 | \$157 | 10.6% | 15,438 | 15,841 | 2.6% | | |
| Injections and Medications | \$82 | \$77 | -6.0% | 12,533 | 12,416 | -0.9% | | |
| Supplies and Devices | \$92 | \$96 | 4.2% | 14,029 | 14,784 | 5.4% | | |
| Dialysis | \$67 | \$62 | -8.0% | 97 | 95 | -2.1% | | |
| Durable Medical Equipment | \$38 | \$36 | -4.2% | 4,615 | 4,723 | 2.3% | | |

Outpatient Medical Detail

| | Utilization | n (Services per 100 | 0) | Price (Allowed An | nount per Service) | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change |
| Major Procedures | 1,965.3 | 1,909.8 | -2.8% | \$693 | \$727 | 4.8% |
| Specialty Drugs (Medical) | 288.6 | 298.9 | 3.6% | \$2,073 | \$2,367 | 14.2% |
| Professional Office Visits | 5,714.5 | 5,657.8 | -1.0% | \$109 | \$117 | 6.7% |
| Emergency Rooms | 2,127.1 | 2,061.2 | -3.1% | \$294 | \$318 | 8.1% |
| Radiology | 1,754.7 | 1,689.9 | -3.7% | \$242 | \$271 | 12.2% |
| Other Outpatient Services | 3,519.9 | 3,671.6 | 4.3% | \$119 | \$114 | -4.7% |
| Laboratory | 7,614.0 | 7,060.0 | -7.3% | \$40 | \$33 | -17.1% |
| Mental Health | 2,591.3 | 2,779.4 | 7.3% | \$103 | \$109 | 5.8% |
| Substance Abuse | 193.6 | 222.5 | 15.0% | \$131 | \$141 | 7.6% |
| PT, OT, Speech Therapy | 4,260.4 | 4,359.8 | 2.3% | \$33 | \$36 | 8.1% |
| Injections and Medications | 807.8 | 785.0 | -2.8% | \$101 | \$98 | -3.3% |
| Supplies and Devices | 1,136.6 | 1,224.7 | 7.8% | \$81 | \$78 | -3.3% |
| Dialysis | 106.8 | 98.9 | -7.4% | \$631 | \$627 | -0.7% |
| Durable Medical Equipment | 204.4 | 207.4 | 1.5% | \$184 | \$173 | -5.5% |

Outpatient Medical Detail: Professional Office Visits


| | | % Visits | | % A | llowed Amt | | Allowe | d Amount/V | isit | Vi | sits per 1000 | |
|-----------------------|------------|------------|--------|----------------|------------|--------|------------|------------|--------|------------|---------------|----------|
| | Jul 2022 - | Jul 2023 - | | Jul 2022 - Jun | Jul 2023 - | | Jul 2022 - | Jul 2023 – | % | Jul 2022 – | Jul 2023 – | |
| | Jun 2023 | Jun 2024 | Change | 2023 | Jun 2024 | Change | Jun 2023 | Jun 2024 | Change | Jun 2023 | Jun 2024 | % Change |
| Specialist Visits | 36.0% | 35.4% | -0.6% | 35.4% | 34.5% | -0.9% | \$126 | \$134 | 5.9% | 1,515 | 1,472 | -2.8% |
| Non-Specialist Visits | 64.0% | 64.6% | 0.6% | 64.6% | 65.5% | 0.9% | \$130 | \$139 | 7.4% | 2,693 | 2,685 | -0.3% |
| Total | 100.0% | 100.0% | | 100.0% | 100.0% | | \$128 | \$137 | 6.9% | 4,208 | 4,157 | -1.2% |




| | Visits per A | llowed Amount |
|-------------------------------|--------------|---------------|
| | 1000 | Per Visit |
| Dermatology | 195 | \$98 |
| Orthopaedic Surgery | 190 | \$130 |
| Cardiovascular Dis/Cardiology | 112 | \$135 |
| Podiatry | 111 | \$93 |
| Emergency Medicine | 70 | \$161 |
| Chiropractor/DCM | 59 | \$84 |
| Ophthalmology | 54 | \$121 |
| Urology | 49 | \$123 |
| Otolaryngology | 53 | \$161 |
| Pain Mgmt/Pain Medicine | 53 | \$115 |
| Surgeon (NEC) | 37 | \$144 |
| Neurology | 39 | \$173 |
| Endocrinology & Metabolism | 39 | \$145 |
| Allergy & Immunology | 41 | \$158 |
| Oncology | 41 | \$159 |
| Top 15 | 1,139 | \$126 |
| All Other Specialists | 337 | \$158 |
| Total All Specialists | 1,472 | \$134 |

Outpatient Medical Detail: Radiology


| | Sei | vices per 100 | 00 | Allowed Amount per Service | | | Allowed Amount PMPY | | | Net Pay PMPY | | |
|------------------|------------|---------------|----------|----------------------------|------------|----------|---------------------|------------|----------|--------------|------------|----------|
| Outpatient | | | | | | | | | | | | |
| Radiology | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | |
| Services | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change |
| CAT Scans | 92.3 | 92.0 | -0.3% | \$426 | \$460 | 8.1% | \$39 | \$42 | 7.7% | \$36 | \$38 | 4.4% |
| MRIs | 116.2 | 119.9 | 3.2% | \$563 | \$568 | 0.9% | \$65 | \$68 | 4.1% | \$61 | \$63 | 4.0% |
| Mammograms | 432.5 | 422.6 | -2.3% | \$121 | \$125 | 3.8% | \$52 | \$53 | 1.5% | \$51 | \$52 | 1.5% |
| PET Scans | 6.7 | 7.8 | 16.7% | \$2,921 | \$2,738 | -6.3% | \$20 | \$21 | 9.4% | \$19 | \$20 | 8.7% |
| Nuclear Medicine | 31.2 | 29.2 | -6.5% | \$755 | \$961 | 27.4% | \$24 | \$28 | 19.2% | \$23 | \$27 | 17.3% |
| Therapeutic | 100.0 | 108.6 | 8.6% | \$1,103 | \$1,217 | 10.3% | \$110 | \$132 | 19.8% | \$109 | \$130 | 19.6% |
| Ultrasounds | 423.2 | 388.3 | -8.3% | \$169 | \$182 | 7.6% | \$72 | \$71 | -1.3% | \$65 | \$64 | -1.1% |
| X-Rays | 520.8 | 488.9 | -6.1% | \$74 | \$79 | 6.8% | \$39 | \$39 | 0.3% | \$33 | \$33 | 0.7% |
| Other | 31.7 | 32.6 | 2.7% | \$112 | \$117 | 4.4% | \$4 | \$4 | 7.2% | \$3 | \$4 | 9.1% |
| Total | 1754.7 | 1689.9 | -3.7% | \$242 | \$271 | 12.2% | \$424 | \$458 | 8.0% | \$399 | \$431 | 7.9% |






Outpatient Medical Detail: Laboratory

| | Ser | vices per 100 | 00 | Allowed | Allowed Amount per Service | | | ed Amount P | MPY | Net Pay PMPY | | |
|------------------------|------------|---------------|----------|------------|----------------------------|----------|------------|-------------|----------|--------------|------------|----------|
| Outpatient Lab | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | |
| Services | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change |
| Chemistry Tests | 3765.7 | 3876.4 | 2.9% | \$21 | \$21 | 0.1% | \$78 | \$80 | 3.1% | \$62 | \$64 | 2.9% |
| Hematology | 584.5 | 589.4 | 0.8% | \$17 | \$14 | -18.3% | \$10 | \$8 | -17.6% | \$7 | \$7 | 7.5% |
| Immunology | 774.5 | 536.2 | -30.8% | \$30 | \$28 | -6.4% | \$23 | \$15 | -35.2% | \$22 | \$13 | -39.1% |
| Microbiology | 1500.9 | 1129.5 | -24.7% | \$67 | \$42 | -37.6% | \$101 | \$47 | -53.0% | \$96 | \$42 | -55.8% |
| Pathology | 464.8 | 426.8 | -8.2% | \$141 | \$135 | -4.6% | \$66 | \$58 | -12.4% | \$61 | \$54 | -11.7% |
| Urinalysis | 320.7 | 315.7 | -1.6% | \$5 | \$5 | 2.5% | \$2 | \$2 | 0.9% | \$1 | \$1 | 1.8% |
| Other | 202.9 | 186.1 | -8.3% | \$130 | \$133 | 2.7% | \$26 | \$25 | -5.8% | \$24 | \$23 | -4.9% |
| Total | 7614.0 | 7060.0 | -7.3% | \$40 | \$33 | -17.1% | \$305 | \$235 | -23.1% | \$273 | \$205 | -24.9% |







Prescription Drug Detail*

Annual Trend

| | | Jul 2022 - | Jul 2023 - | |
|------------|-------------------------------|------------|------------|----------|
| | | Jun 2023 | Jun 2024 | % Change |
| Total | Allowed Amount PMPY | \$2,096 | \$2,440 | 16.4% |
| ₽ | Net Pay PMPY | \$1,978 | \$2,147 | 8.5% |
| | Out of Pocket PMPY | \$110 | \$122 | 10.7% |
| | Patients per 1000 | 826.9 | 768.2 | -7.1% |
| | Allowed Amount per Day Supply | \$4.48 | \$5.18 | 15.5% |
| | Days Supply PMPY | 467.7 | 471.4 | 0.8% |
| der | Allowed Amount PMPY | \$106 | \$156 | 47.3% |
| Ö | Net Pay PMPY | \$100 | \$146 | 46.9% |
| Mail Order | Out of Pocket PMPY | \$6 | \$8 | 32.4% |
| Σ | Patients per 1000 | 44.3 | 48.3 | 9.1% |
| | Allowed Amount per Day Supply | \$2.68 | \$4.02 | 50.0% |
| | Days Supply PMPY | 39.5 | 38.8 | -1.8% |
| Retail | Allowed Amount PMPY | \$988 | \$1,142 | 15.7% |
| Re | Net Pay PMPY | \$887 | \$1,029 | 16.1% |
| | Out of Pocket PMPY | \$95 | \$106 | 11.6% |
| | Patients per 1000 | 823.6 | 763.3 | -7.3% |
| | Allowed Amount per Day Supply | \$2.35 | \$2.70 | 14.7% |
| | Days Supply PMPY | 420.0 | 423.6 | 0.9% |
| alt, | Allowed Amount PMPY | \$1,002 | \$1,141 | 13.8% |
| Specialty | Net Pay PMPY | \$992 | \$971 | -2.1% |
| Spe | Out of Pocket PMPY | \$8 | \$7 | -15.7% |
| | Patients per 1000 | 40.8 | 42.1 | 3.2% |
| | Allowed Amount per Day Supply | \$122.82 | \$128.11 | 4.3% |
| erative | Days Supply PMPY | 8.2 | 8.9 | 9.1% |
| | | | | |





^{*}Specialty drugs on this slide includes drugs covered under the prescription drug benefit and excludes drugs covered under the medical plans.

Prescription Drug Detail: Non-Specialty Drugs

Annual Trend

| | Allow | ed Amount | PMPY | Net Pay PMPY | | Allowed | Amt per Da | mt per Days Supply Days So | | | MPY Generic Efficiency | | | | |
|----------------------------|------------|------------|-------------|--------------|------------|----------|------------|----------------------------|----------|------------|------------------------|----------|------------|------------|----------|
| | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | | Jul 2022 - | Jul 2023 - | |
| Therapeutic Class | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change |
| Hormones & Synthetic Subst | \$498 | \$681 | 36.7% | \$470 | \$650 | 38.2% | \$6 | \$8 | 30.5% | 82 | 86 | 4.7% | 93.3% | 94.3% | 1.2% |
| Central Nervous System | \$240 | \$230 | -4.0% | \$211 | \$201 | -5.0% | \$2 | \$2 | -5.6% | 115 | 117 | 1.7% | 97.0% | 97.5% | 0.5% |
| Cardiovascular Agents | \$48 | \$59 | 21.4% | \$36 | \$44 | 23.7% | \$0 | \$0 | 21.1% | 120 | 120 | 0.2% | 100.0% | 99.9% | 0.0% |
| Blood Form/Coagul Agents | \$48 | \$51 | 6.5% | \$46 | \$49 | 6.0% | \$8 | \$9 | 4.9% | 6 | 6 | 1.5% | 99.9% | 99.8% | -0.1% |
| Gastrointestinal Drugs | \$38 | \$40 | 5.0% | \$34 | \$35 | 2.5% | \$2 | \$2 | 1.6% | 25 | 26 | 3.3% | 99.9% | 99.9% | 0.0% |
| Serums, Toxoids, Vaccines | \$23 | \$37 | 59.5% | \$23 | \$37 | 59.6% | \$55 | \$109 | 96.0% | 0 | 0 | -18.6% | 100.0% | 100.0% | 0.0% |
| Anti-Infective Agents | \$24 | \$31 | 27.8% | \$18 | \$24 | 31.6% | \$2 | \$2 | 23.4% | 12 | 13 | 3.6% | 100.0% | 100.0% | 0.0% |
| Autonomic Drugs | \$33 | \$29 | -13.0% | \$29 | \$24 | -16.4% | \$3 | \$2 | -12.9% | 12 | 12 | -0.1% | 99.9% | 99.9% | 0.1% |
| Eye, Ear, Nose Throat | \$28 | \$26 | -4.1% | \$23 | \$22 | -4.6% | \$2 | \$3 | 48.0% | 13 | 9 | -35.2% | 98.1% | 97.6% | -0.5% |
| Skin & Mucous Membrane | \$27 | \$25 | -5.2% | \$23 | \$21 | -8.6% | \$3 | \$2 | -14.5% | 9 | 10 | 10.8% | 98.7% | 98.7% | 0.0% |
| All Other Values | \$86 | \$88 | 3.1% | \$72 | \$68 | -5.2% | \$1 | \$1 | 4.4% | 65 | 64 | -1.2% | 99.7% | 99.6% | 0.0% |
| Total | \$1,094 | \$1,299 | 18.7% | \$986 | \$1,176 | 19.2% | \$2 | \$3 | 18.0% | 460 | 462 | 0.6% | 98.1% | 98.4% | 0.3% |



Specialty Drug Detail¹

| | Allowed Amount | | | Patients | | | Allowed Amount per Patient | | | |
|------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|----------------------------|------------------------|----------|--|
| | Jul 2022 – Jun 2023 | Jul 2023 – Jun 2024 | % Change | Jul 2022 - Jun 2023 | Jul 2023 - Jun 2024 | % Change | Jul 2022 - Jun 2023 | Jul 2023 - Jun 2024 | % Change | |
| Medical Specialty | \$59,869,309 | \$72,073,837 | 20.4% | 3,432 | 3,733 | 8.8% | \$17,444 | \$19,307 | 10.7% | |
| Prescription Specialty | \$100,284,629 | \$116,244,886 | 15.9% | 4,482 | 4,708 | 5.0% | \$22,375 | \$24,691 | 10.4% | |

| Top 10 Specialty Drugs Through Medical Plans | Allowed Amount | Patients | Allowed/Patient |
|---|----------------|----------|-----------------|
| J9271 Inject pembrolizumab 1 mg | \$7,829,832 | 62 | \$126,288 |
| J2350Inject, ocrelizumab, 1 mg | \$3,775,147 | 54 | \$69,910 |
| J2506Inject, pegfilgrastim, excl biosimilar, 0.5 mg | \$3,325,152 | 72 | \$46,183 |
| J9299Inject nivolumab 1 mg | \$2,654,322 | 18 | \$147,462 |
| J9144Inj, daratumumab, 10 mg and hyaluronidase-fihj | \$2,204,141 | 17 | \$129,655 |
| J3380Inject, vedolizumab, intravenous, 1 mg | \$2,170,450 | 53 | \$40,952 |
| 96413 CHEMOTX ADMN IV NFS TQ UP 1 HR | \$1,904,266 | 565 | \$3,370 |
| J3241Inject, teprotumumab-trbw, 10 mg | \$1,722,178 | 3 | \$574,059 |
| J2323Injection natalizumab, 1 mg | \$1,634,897 | 14 | \$116,778 |
| J0585 Injection onabotulinumtoxinA, 1 unit | \$1,297,556 | 319 | \$4,068 |
| Total Top 10 | \$27,220,383 | 858 | \$31,725 |
| Percent of Overall Total (Medical Specialty) | 37.8% | 23.0% | |

¹Specialty drugs are defined in a Merative service category group and include drugs paid under the prescription benefit and the medical benefit. Although there is no consensus definition, the continuum of drugs included may have the following characteristics: relatively costly (at least \$670 per month for a 30-day supply, according to CMS); often injected or infused; involve a significant degree of patient education, monitoring and management; require special preparation, handling or monitoring; and may be biologically created vs. a chemical compound.

Specialty Drug Detail

| Top 15 Through the Prescription Plan | | |
|---|----------------|----------|
| | Allowed Amount | Patients |
| HUMIRA | \$9,863,799 | 214 |
| STELARA | \$8,317,456 | 86 |
| TREMFYA | \$6,235,281 | 109 |
| SKYRIZI | \$5,346,085 | 215 |
| DUPIXENT PEN | \$5,145,342 | 94 |
| ENBREL | \$2,814,755 | 63 |
| COSENTYX | \$2,551,337 | 55 |
| TALTZ | \$2,507,987 | 44 |
| TRIKAFTA | \$2,239,980 | 7 |
| DUPIXENT PFS | \$2,146,159 | 89 |
| BIKTARVY | \$2,066,174 | 67 |
| OTEZLA | \$1,948,282 | 71 |
| SPRYCEL | \$1,809,986 | 53 |
| RINVOQ | \$1,788,985 | 15 |
| VERZENIO | \$1,699,651 | 17 |
| Total Top 15 | \$56,481,260 | 1,199 |
| Percent of Overall Total (Rx Specialty) | 48.6% | 25.5% |


Mental Health and Substance Abuse Detail

| | M | lental Health | | Substance Abuse | | | | |
|-----------------------------|------------|---------------|----------|-----------------|------------|----------|--|--|
| | Jul 2022 – | Jul 2023 – | | Jul 2022 – | Jul 2023 – | | | |
| | Jun 2023 | Jun 2024 | % Change | Jun 2023 | Jun 2024 | % Change | | |
| Overall | | | | | | | | |
| Patients per 1000 Inpatient | 4.3 | 4.2 | -2.4% | 1.5 | 1.5 | 1.3% | | |
| Pats per 1000 Outpatient | 210.1 | 218.5 | 4.0% | 8.9 | 9.5 | 5.9% | | |
| Inpatient | | | | | | | | |
| Allow Amt PMPY Adm Acute | \$55 | \$61 | 11.6% | \$26 | \$31 | 19.1% | | |
| Net Pay PMPY Adm Acute | \$52 | \$59 | 12.9% | \$25 | \$29 | 17.5% | | |
| Allow Amt Per Adm Acute | \$13,576 | \$15,745 | 16.0% | \$13,324 | \$12,855 | -3.5% | | |
| Days LOS Admit Acute | 10.5 | 10.2 | -2.6% | 10.4 | 9.0 | -13.4% | | |
| Admits Per 1000 Acute | 4.0 | 3.9 | -3.7% | 1.9 | 2.4 | 23.4% | | |
| Outpatient | | | | | | | | |
| Allow Amt PMPY OP Med | \$262 | \$296 | 12.9% | \$25 | \$31 | -13.8% | | |
| Net Pay PMPY OP Med | \$240 | \$271 | 12.9% | \$23 | \$29 | -13.4% | | |
| Allow Amt Per Svc OP Med | \$104 | \$111 | 6.6% | \$130 | \$141 | 12.8% | | |
| Svcs Per 1000 OP Med | 2516.0 | 2666.0 | 6.0% | 193.0 | 221.3 | -23.6% | | |

© 2024 Merative

23

Preventive Visits and Screening Overview





Clinical Overview

| Annual Trend: Conditions of Interest | Allowed Amount PMPY (Medical) | | | Patients per 1000 | | | Allowed Amount per Patient (Medical) | | |
|--------------------------------------|-------------------------------|------------|--------|-------------------|------------|--------|--------------------------------------|-------------|--------|
| | Jul 2022 – | Jul 2023 – | | Jul 2022 – | Jul 2023 – | | Jul 2022 – | Jul 2023 – | |
| | Jun 2023 | Jun 2024 | Change | Jun 2023 | Jun 2024 | Change | Jun 2023 | Jun 2024 | Change |
| Asthma | \$29.54 | \$27.50 | -6.9% | 38.0 | 37.9 | -0.3% | \$708.64 | \$661.88 | -6.6% |
| Cancer - Breast | \$104.31 | \$161.67 | 55.0% | 7.2 | 7.2 | -0.4% | \$13,125.80 | \$20,429.69 | 55.6% |
| Cancer - Colon | \$28.62 | \$30.44 | 6.3% | 1.6 | 1.6 | -2.3% | \$15,908.27 | \$17,318.70 | 8.9% |
| Cancer - Lung | \$33.50 | \$37.97 | 13.4% | 1.2 | 1.2 | -6.8% | \$24,458.87 | \$29,748.02 | 21.6% |
| Cancer - Skin | \$31.03 | \$33.01 | 6.4% | 28.5 | 29.2 | 2.4% | \$992.60 | \$1,031.69 | 3.9% |
| Cerebrovascular Disease | \$81.22 | \$94.94 | 16.9% | 11.8 | 11.8 | -0.2% | \$6,264.39 | \$7,341.96 | 17.2% |
| Chronic Obstruc Pulm Dis(COPD) | \$13.32 | \$11.24 | -15.7% | 5.4 | 5.3 | -1.4% | \$2,259.30 | \$1,933.11 | -14.4% |
| Congestive Heart Failure | \$23.90 | \$15.11 | -36.8% | 3.3 | 3.4 | 4.5% | \$6,660.05 | \$4,028.25 | -39.5% |
| Coronary Artery Disease | \$104.49 | \$103.19 | -1.2% | 14.7 | 15.0 | 2.0% | \$6,476.07 | \$6,270.88 | -3.2% |
| Diabetes | \$102.26 | \$104.09 | 1.8% | 95.1 | 101.8 | 7.0% | \$980.04 | \$932.41 | -4.9% |
| Hypertension, Essential | \$76.03 | \$85.25 | 12.1% | 119.9 | 117.8 | -1.7% | \$577.85 | \$659.57 | 14.1% |
| Mental Hlth - Depression | \$123.21 | \$137.15 | 11.3% | 96.7 | 100.8 | 4.2% | \$1,160.89 | \$1,240.62 | 6.9% |
| Osteoarthritis | \$200.14 | \$181.57 | -9.3% | 62.8 | 62.2 | -1.0% | \$2,905.87 | \$2,662.84 | -8.4% |
| Renal Function Failure | \$112.34 | \$95.69 | -14.8% | 11.0 | 11.4 | 4.4% | \$9,349.69 | \$7,631.82 | -18.4% |
| Spinal/Back Disord, Low Back | \$184.49 | \$189.30 | 2.6% | 98.4 | 97.2 | -1.3% | \$1,708.04 | \$1,776.16 | 4.0% |
| Pneumonia | \$23.58 | \$37.90 | 60.7% | 7.5 | 8.9 | 18.4% | \$2,852.33 | \$3,871.53 | 35.7% |
| Pregnancy | \$303.60 | \$296.54 | -2.3% | 25.0 | 24.3 | -2.9% | \$11,072.27 | \$11,141.13 | 0.6% |

Risk Profile¹ (Based on FY23 Claims Experience)

| | Member Age Avg | Allowed Amount | Allow Amt PMPY | Patients |
|------------|----------------|----------------|----------------|----------|
| Healthy | 25.1 | \$21,306,114 | \$702 | 27,410 |
| Stable | 29.8 | \$63,994,131 | \$2,624 | 25,936 |
| At Risk | 39.8 | \$162,793,182 | \$6,605 | 26,519 |
| Struggling | 46.1 | \$331,567,653 | \$19,273 | 18,487 |
| In Crisis | 50.8 | \$303,273,429 | \$88,302 | 3,896 |





Risk Categories

- **Healthy** represents nearly 50% of the privately insured under-65 U.S. population, who account for less than 5% of total healthcare cost. Most patients in this category are infrequent or non-utilizers of the healthcare system, most often being treated for occasional low severity acute conditions.
- **Stable** represents nearly 25% of the privately insured under-65 U.S. population, who account for 10-15% of total healthcare cost. Most patients in this category are somewhat active utilizers of the healthcare system, most often being treated for low-severity acute conditions.
- At Risk represents between 15 and 20% of the privately insured under-65 U.S. population, who account for 20-25% of total healthcare cost. Most patients in this category are active utilizers of the healthcare system, most often being treated for multiple medium-severity acute conditions and/or low-severity chronic conditions.
- **Struggling** represents between 5 and 10% of the privately insured under-65 U.S. population, who account for 25-30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple high-severity acute conditions and/or medium-severity chronic conditions.
- In-Crisis represents the top 2% of the privately insured under-65 U.S. population, who account for approximately 30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple severe acute and/or chronic conditions.